Athira Pharma (NASDAQ:ATHA) Insider Martin Javier San Sells 1,644 Shares of Stock

Athira Pharma, Inc. (NASDAQ:ATHA) insider Martin Javier San sold 1,644 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $6.88, for a total transaction of $11,310.72. Following the completion of the transaction, the insider owned 10,189 shares of the company’s stock, valued at approximately $70,100.32. This trade represents a 13.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Athira Pharma Trading Down 5.5%

Shares of ATHA stock opened at $6.58 on Tuesday. Athira Pharma, Inc. has a 1-year low of $2.20 and a 1-year high of $8.36. The stock has a market cap of $25.93 million, a price-to-earnings ratio of -0.68 and a beta of 2.79. The stock has a 50-day moving average of $5.03 and a 200-day moving average of $4.27.

Athira Pharma (NASDAQ:ATHA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($1.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($1.51). Sell-side analysts forecast that Athira Pharma, Inc. will post -2.35 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ATHA. Weiss Ratings reissued a “sell (d-)” rating on shares of Athira Pharma in a research note on Wednesday, October 8th. Mizuho set a $4.00 target price on Athira Pharma in a report on Friday, September 19th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Athira Pharma has a consensus rating of “Sell” and a consensus price target of $4.00.

Institutional Trading of Athira Pharma

An institutional investor recently raised its position in Athira Pharma stock. BML Capital Management LLC increased its position in shares of Athira Pharma, Inc. (NASDAQ:ATHA) by 0.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,230,667 shares of the company’s stock after buying an additional 30,000 shares during the quarter. Athira Pharma comprises about 0.7% of BML Capital Management LLC’s portfolio, making the stock its 17th biggest position. BML Capital Management LLC owned approximately 8.27% of Athira Pharma worth $976,000 at the end of the most recent reporting period. 57.12% of the stock is owned by hedge funds and other institutional investors.

About Athira Pharma

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.